Furthermore, we demonstrated that RPL34-AS1 acted as an endogenous sponge of miR-575 and subsequently promoted ACAA2 expression to inhibit ESCC cells proliferation, invasion and migration, suggesting that RPL34-AS1 may be used as a therapeutic target for patients with ESCC. This evidence concerns the gene RPL34 and esophageal squamous cell carcinoma.